VIR News and Press, Vir Biotechnology Inc. From 05/20/22

Vir Biotechnology (NASDAQ:VIR) announced on Friday that its Chinese partner WuXi Biologics (OTCPK:WXXWY) (OTCPK:WXIBF) ended its partnership for development and manufacturing for several of company’s antibody drugs including the COVID-19 antibody therapy sotrovimab. Per the terms of th...

SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio...

U.S. President Joe Biden issued a proclamation on Thursday ordering flags at the White House and all federal buildings to be flown at half-staff in commemoration of 1 million American lives lost due to COVID-19. A Reuters tally indicated on Thursday that the U.S. has recor...

Vir Biotechnology press release (NASDAQ:VIR): Q1 GAAP EPS of $3.85 beats by $0.31. Revenue of $1.23B (+61400.0% Y/Y) beats by $418.95M. Shares +3%. CEO comment: “At our recent Hepatitis Portfolio R&D Day, we shared encouraging initial data from our Phase 2 MARCH trial evaluating he...

– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the first quarter – – Encouraging initi...

Vir Biotechnology had obtained about $917.2 million of sotrovimab collaboration revenue in 2021; Expects about $1.1 billion in revenues with all doses delivered by 1st half of 2022. About 95% of patients who took VIR-2218 plus PEG-IFN-a achieved Hepatitis B surface antigen ((HBsA...

– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today , Wednesday, April 27, at 12:00 pm ET / 9:00 am PT – SAN F...

GlaxoSmithKline's (NYSE:GSK) Q1 revenue rose on the back of strong performance from Specialty Medicines segment, while the company reconfirmed its guidance and said that the spin-off of consumer unit Haleon was on track for July. Q1 sales rose +32% Y/Y (at AER) Y/Y £9.78B. The compa...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022. The update will be provided via a pres...